Plasma Levels of Brain Natriuretic Peptide: A Potential Marker for HIV-Related Cardiomyopathy

Carrillo-Jimenez, Rodolfo; Lamas, Gervasio A.; Hennekens, Charles H.

doi:10.1177/107424840200700302

Cited by 13 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Elevated levels of BNP have been described in case reports in HIV patients with HIV-related cardiomyopathy [14,20]. In another small study the incidence of myocardial dysfunction in an HIV-infected population receiving state-of-the-art treatment was examined in 91 HIV-infected patients with a radionuclide left and right ventriculography as well as measurement of BNP [16].…”

Section: Discussionmentioning

confidence: 99%

“…Natriuretic peptides have been studied in a limited number of HIV patients with left-ventricular dysfunction, myocarditis or pulmonary hypertension [14–16]. In a sample of participants from the Women's Interagency HIV Study (WIHS), an ongoing, multicenter study of natural history of HIV disease in women, it was shown that HIV-infected women had higher mean NT-pro-BNP levels compared to HIV-uninfected women, but that the differences were attributable to factors such as anemia, kidney disease, and hepatitis co-infection [17].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients

Duprez

Neuhaus

Tracy

et al. 2011

Aids

View full text Add to dashboard Cite

Background Cardiovascular disease (CVD) is increasing in HIV-infected patients. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a significant predictor of CVD in the general population. We aimed to quantify the risk of CVD events associated with NT-proBNP at baseline in the Strategies for Management of Anti-Retroviral Therapy study. Methods In a nested case–control study, NT-proBNP was measured at baseline in 186 patients who experienced a CVD event over an average of 2.8 years of follow-up and in 329 matched controls. Odds ratios (ORs) associated with baseline levels of NT-proBNP for CVD were estimated using conditional logistic regression. Results At baseline median NT-proBNP [interquartile range (IQR)] was 48.1 (18.5, 112.9) pg/ml in patients who developed a CVD event and 25.7 (12.4, 50.2) pg/ml in controls. The unadjusted OR for the highest versus the lowest quartile was 3.7 [95% confidence interval (CI) 2.1–6.5, P < 0.0001]. After adjustment for baseline covariates and CVD risk factors, OR was 2.8 (95% CI 1.4–5.6, P = 0.003); with additional adjustment for IL-6, high-sensitivity C-reactive protein and D-dimer, OR was 2.3 (95% CI 1.1–4.9, P = 0.02). Conclusions Higher levels of NT-proBNP are associated with increased risk of CVD in HIV patients after considering established CVD risk factors and markers for inflammation and thrombosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients

Duprez

Neuhaus

Tracy

et al. 2011

Aids

View full text Add to dashboard Cite

show abstract

“…Few prior studies have assessed natriuretic peptide levels and cardiac function in HIV-infected populations12–15 and none has specifically examined NT-Pro-BNP levels. Carillo-Jimenez found serum levels inversely related to LV function in 10 HIV-infected patients assessed by echocardiography 12.…”

Section: Discussionmentioning

confidence: 99%

“…Cardiovascular (CV) disease is an increasing concern among patients with HIV infection 8,9. Although natriuretic peptide levels have been proposed to be a neurohumoral marker of CV risk,10,11 few prior studies have evaluated such levels in HIV infection 12–15. Accordingly, the objectives of the present study were to identify clinical factors associated with elevated NT-pro-BNP in HIV-infected and -uninfected women and to further investigate the effect of these risk factors on NT-pro-BNP levels in HIV-infected women.…”

Section: Introductionmentioning

confidence: 99%

Elevated NT-pro-BNP Levels Are Associated with Comorbidities among HIV-Infected Women

Mansoor

Althoff

Gange

et al. 2009

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

HIV infection is associated with left ventricular (LV) dysfunction and accelerated atherosclerosis. These conditions result in elevation of plasma natriuretic peptide (NP) levels. The present study compares N-terminal-pro-BNP (NT-pro-BNP) levels in HIV-infected and -uninfected women and identifies factors influencing NT-pro-BNP levels in HIV-infected women. A total of 454 HIV-infected and 200 HIV-uninfected participants from the Women’s Interagency HIV Study (WIHS) had NT-pro-BNP determination. Elevated NT-pro-BNP level was defined using previously determined age stratified cut-off values of >164 ng/liter (age <60 years) and >225 (age ≥60 years). HIV-infected women were older (41.6 ± 8.9 vs. 38.9 ± 10.5 years, p <0.01) and were more likely to have anemia, hepatitis C virus (HCV) antibodies, and kidney dysfunction than HIV-uninfected women. HIV-infected women had significantly higher NT-pro-BNP levels (142.4 ± 524.8 vs. 73.6 ± 115.1 ng/liter, p = 0.01) and a higher prevalence of elevated NT-pro-BNP (12.1% vs. 7.5%; p = 0.08). In univariate analyses, elevated NT-pro-BNP was significantly associated with age, systolic BP, hypertension, anemia, triglyceride levels, kidney disease, and HCV seropositivity, but not HIV infection. In multivariate analysis, elevated NT-pro-BNP levels were significantly associated with anemia and kidney function, and had a borderline association with the presence of HCV antibodies. Among HIV-infected women, NT-pro-BNP levels were not independently associated with measures of severity of infection or with HAART use. Although HIV-infected women have higher NT-pro-BNP levels than HIV-uninfected women, the differences are due to non-HIV factors such as anemia, kidney disease, and HCV coinfection. These findings suggest that natriuretic peptide levels are a global marker of comorbidity in the setting of HIV infection.

show abstract

“…Bisherige Arbeiten, die die BNP-Konzentration bei HIV-infizierten Patienten berücksichtigten, fokussierten auf Teilaspekte oder nutzten den Biomarker zur Patientenselektion [17][18][19] …”

unclassified

Wertigkeit des Biomarkers BNP bei HIV-infizierten Patienten

Neumann

Reinsch²,

Neuhaus

et al. 2009

Herz

View full text Add to dashboard Cite

show abstract

Plasma Levels of Brain Natriuretic Peptide: A Potential Marker for HIV-Related Cardiomyopathy

Cited by 13 publications

References 21 publications

N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients

N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients

Elevated NT-pro-BNP Levels Are Associated with Comorbidities among HIV-Infected Women

Wertigkeit des Biomarkers BNP bei HIV-infizierten Patienten

Contact Info

Product

Resources

About